Capricor Therapeutics (NASDAQ:CAPR) Stock Price Down 5% - What's Next?

Capricor Therapeutics, Inc. (NASDAQ:CAPR - Get Free Report)'s stock price was down 5% during mid-day trading on Thursday . The company traded as low as $11.02 and last traded at $10.85. Approximately 517,554 shares were traded during trading, a decline of 74% from the average daily volume of 1,981,814 shares. The stock had previously closed at $11.42.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on CAPR shares. Cantor Fitzgerald reissued an "overweight" rating and set a $30.00 price objective on shares of Capricor Therapeutics in a research report on Wednesday, May 14th. Wall Street Zen cut Capricor Therapeutics from a "hold" rating to a "sell" rating in a report on Thursday, May 22nd. Alliance Global Partners initiated coverage on Capricor Therapeutics in a report on Monday, June 30th. They set a "buy" rating and a $20.00 target price for the company. Jones Trading lowered their target price on Capricor Therapeutics from $40.00 to $29.00 and set a "buy" rating for the company in a report on Wednesday, June 25th. Finally, B. Riley initiated coverage on Capricor Therapeutics in a report on Thursday, June 26th. They set a "buy" rating and a $21.00 target price for the company. One equities research analyst has rated the stock with a sell rating, eight have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $24.67.

Capricor Therapeutics Trading Down 33.0%

The firm has a 50 day moving average price of $10.42 and a 200-day moving average price of $12.16. The firm has a market cap of $349.00 million, a PE ratio of -5.38 and a beta of 0.82.

Capricor Therapeutics (NASDAQ:CAPR - Get Free Report) last posted its earnings results on Tuesday, May 13th. The biotechnology company reported ($0.53) earnings per share for the quarter, missing the consensus estimate of ($0.33) by ($0.20). The business had revenue of $2.73 million for the quarter, compared to analysts' expectations of $3.16 million. Capricor Therapeutics had a negative return on equity of 62.42% and a negative net margin of 181.71%. During the same quarter in the previous year, the firm earned ($0.31) EPS. Equities analysts forecast that Capricor Therapeutics, Inc. will post -1.21 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Capricor Therapeutics

Several institutional investors have recently added to or reduced their stakes in CAPR. Bank of New York Mellon Corp lifted its stake in Capricor Therapeutics by 32.6% during the fourth quarter. Bank of New York Mellon Corp now owns 84,027 shares of the biotechnology company's stock worth $1,160,000 after purchasing an additional 20,638 shares during the last quarter. Charles Schwab Investment Management Inc. increased its holdings in shares of Capricor Therapeutics by 51.5% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 111,336 shares of the biotechnology company's stock valued at $1,536,000 after purchasing an additional 37,868 shares during the period. AlphaQuest LLC acquired a new position in shares of Capricor Therapeutics in the fourth quarter valued at approximately $78,000. Swiss National Bank acquired a new stake in shares of Capricor Therapeutics in the 4th quarter valued at approximately $930,000. Finally, Intech Investment Management LLC acquired a new stake in Capricor Therapeutics in the fourth quarter valued at $228,000. Hedge funds and other institutional investors own 21.68% of the company's stock.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc NASDAQ: CAPR is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.